Abstract
English
Highlights
Oxycodone controlled-release is a potent opioid analgesic
There was no difference in postoperative pain scores in patients who were pre-medicated with oral oxycodone controlled-release as compared with placebo
Of particular relevance are two of the studies, which have been performed in patients undergoing ambulatory laparoscopic gynaecological surgery
Summary
We aim to assess the efficacy of pre-medication of oral oxycodone controlled-release in the reduction of postoperative pain in ambulatory laparoscopic gynaecological surgery. Materials and Methods A randomised, double blind, placebocontrolled trial was performed This was conducted in 60 patients undergoing ambulatory laparoscopic gynaecological surgery. Oxycodone controlled-release (CR) (OxyContinTM®, Mundipharma Pharmaceutical, UK) is a potent opioid analgesic with a long duration of action and almost twice the potency of oral morphine[5]. It has a biphasic absorption pattern with an initial absorption of about 40% of the drug producing analgesia 1 h after consumption in most patients. The effects of oxycodone may have been perceptible without the various modes of analgesia
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
